The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 53 Respiratory Patient Groups (2nd Edition)

  • ID: 4416864
  • Report
  • 94 pages
  • PatientView
1 of 3

These results are derived from a global review of pharma’s corporate reputation (conducted November 2016 to early-February 2017).
This report is based on the opinions of 53 respiratory patient groups, from Finland (8), USA (5), Spain (4), and 19 other countries.  
The specialty areas of the respiratory patient groups: asthma (8), cystic fibrosis (8), COPD (7), allergy (2), lung cancer (2), and respiratory conditions in general (26).
11 pharma companies are included in this 2016 respiratory analysis:

  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • GSK
  • Merck & Co
  • Novartis
  • Pfizer
  • Roche
  • Sandoz
  • Teva

The 11 companies were chosen because a minimum of 19 respiratory patient groups declared familiarity with each one.
18 patient groups (from Austria, Canada, the Czech Republic, Finland, France, Ireland, the Netherlands, New Zealand, Spain, Sweden, Switzerland, the United Kingdom, and the USA) provided comments on pharma's corporate reputation.

THE QUESTIONNAIRE

Industry-wide questions:

  • How the pharma industry’s corporate reputation compares with that of other healthcare industries.
  • How the pharma industry’s corporate reputation has changed over the past five years.
  • How good or bad the pharma industry is at various activities of relevance to patients and patient groups.

7 indicators show the corporate reputation of individual pharma companies:

  • Patient centricity.
  • Information for patients.
  • Patient safety.
  • Usefulness of products.
  • Transparency.
  • Integrity.
  • Patient-group relationships (new for 2016).

INDUSTRY-WIDE FINDINGS

  • 51.0% of 2016's 53 respondent respiratory patient groups thought that the pharma industry had an “Excellent” or “Good” corporate reputation (37.9% of patient groups worldwide thought the same).
  • However, only 15% of the respiratory patient groups thought that the pharma industry’s corporate reputation had improved over the past five years (compared with 23% of respondents therapy wide). As many as 33% of respiratory patient groups thought that pharma’s corporate reputation had declined (against 29% therapy wide).
  • Respiratory patient groups were, on the whole, positive about many of the pharma industry’s activities in 2016. Some 77% stated that pharma was “Excellent” or “Good” at creating high-quality products (compared with 64% of patient groups therapy wide).
  • Nonetheless, respiratory  patient groups sent pharma a clear message in 2016: the key task for improving corporate reputation (out of a list of 15 potential choices) is to do more to create high-quality, useful products (noted by 21% of the respiratory patient groups, but by only 11% of patient groups therapy wide).

PHARMA COMPANIES and RESPIRATORY PATIENT GROUPS

  • The company with which respiratory patient groups were most familiar in 2016 was Novartis (83% of the 53 respondent respiratory patient groups were familiar with the company).

INDIVIDUAL COMPANY FINDINGS—RESPIRATORY

  • GSK ranked overall 1st in 2016 for corporate reputation among the 11 pharma companies, when judged by respiratory patient groups familiar with the company. GSK also ranked 1st for each of the seven indicators of corporate reputation.
  • Roche ranked 1st among the 11 pharma companies for the corporate-reputation indicator of integrity, when judged by respiratory patient groups familiar with the company.
  • GSK was also positioned overall 1st in 2016 for corporate reputation among the 11 pharma companies, when judged by respiratory patient groups that worked with the company. GSK was also positioned 1st among these patient groups for four of the seven indicators of corporate reputation: patient centricity; patient information; high-quality products; and patient-group partnerships. AstraZeneca was positioned 1st among its respiratory patient-group partners for patient safety. Pfizer was positioned 1st among its respiratory patient-group partners for both transparency and integrity.

HIGHS and LOWS—RESPIRATORY

  • Pharma companies’ PCRIs among respiratory patient groups familiar with each company, 2016 v. 2015: ordered according to the difference between the PCRI values for the two years (high to low)
  • When the Patient Corporate Reputation Index (PCRI) is applied, the final 2016 rankings of companies among respiratory patient groups familiar with them can be compared with those attained by the same companies among respiratory patient groups familiar with each company in 2015. Such analysis shows that the company which made the biggest improvement in its overall corporate-reputation rankings among respiratory patient groups that were familiar with it, 2015-2016, was AstraZeneca.
READ MORE
Note: Product cover images may vary from those shown
2 of 3

Executive summary.
Respiratory patient-group relationships with 11 pharma companies.
Industry-wide findings from respiratory patient groups.
Respiratory patient groups on improving corporate reputation.
Rankings of the 11 pharma companies among respiratory patient groups FAMILIAR with them.
Positionings of the 11 pharma companies among PARTNER respiratory patient groups.
Profiles of the 11 pharma companies.
Comments from respondent respiratory patient groups.
Profile of the 53 respondent respiratory patient groups.

COMPANY PROFILES

Charts and tables for each of the 11 pharma companies:

  • Number of respiratory patient groups claiming familiarity with the company, 2016.
  • Number of respiratory patient groups saying that they had a working relationship with the company, 2016.
  • Profile of the respondent respiratory patient groups familiar with the company: specialties, country headquarters, and geographic remit.
  • Percentage of the respiratory patient groups that worked with the company—but which also worked with other companies, 2016.
  • The company’s average score for the indicators of corporate reputation among respiratory patient groups familiar with the company, 2016 v. 2015.
  • The company’s scores among respiratory patient groups familiar with the company, and which worked with the company, for each of the seven indicators of corporate reputation, 2016.
  • The company’s overall rankings for corporate reputation among patient groups familiar with the company: respiratory v. therapy wide. All 2016.
  • The company’s positioning for corporate reputation among patient groups which worked with the company: respiratory v. therapy wide. All 2016.
  • The company’s rankings among patient groups for the seven indicators of corporate reputation, 2016: respiratory v. therapy wide; familiar with v. worked with.
  • Performance of the company at corporate reputation in different therapy/geographic areas, compared with its own average among respiratory patient groups, 2016.
  • The company’s Patient Corporate Reputation Index  (PCRI), respiratory v. therapy wide, 2016.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll